Skip to main content
Erschienen in: Archives of Virology 5/2010

01.05.2010 | Original Article

Effect of foot-and-mouth disease virus capsid precursor protein and 3C protease expression on bovine herpesvirus 1 replication

verfasst von: Constanze Klopfleisch, Luu Quang Minh, Katrin Giesow, Stephen Curry, Günther M. Keil

Erschienen in: Archives of Virology | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Several reports have previously shown that expression of the foot-and-mouth disease virus (FMDV) capsid precursor protein encoding region P1-2A together with the 3C protease (P1-2A/3C) results in correct processing of the capsid precursor into VP0, VP1 and VP3 and formation of FMDV capsid structures that are able to induce a protective immune response against FMDV challenge after immunization using naked DNA constructs or recombinant viruses. To elucidate whether bovine herpesvirus 1 (BHV-1) might also be suitable as a viral vector for empty capsid generation, we aimed to integrate a P1-2A/3C expression cassette into the BHV-1 genome, which, however, failed repeatedly. In contrast, BHV-1 recombinants that expressed an inactive 3C protease or the P1-2A polyprotein alone could be easily generated, although the recombinant that expressed P1-2A exhibited a defect in direct cell–cell spread and release of infectious particles. These results suggested that expression of the original, active FMDV 3C protease is not compatible with BHV-1 replication. This conclusion is supported by the isolation of recombinant BHV-1/3C*, which contained mutations within the 3C ORF (3C* ORF)—probably introduced spontaneously during generation of BHV-1/3C*—instead of the authentic 3C ORF contained in the transfer plasmids. Within the 3C* ORF, the codons for glycine 38 and phenylalanine 48 were both substituted by codons for serine. The resulting 3C* protease exhibits a highly reduced activity for proteolytic processing of the P1-2A polyprotein and thus might be a good candidate for the generation of live attenuated FMDV variants.
Literatur
1.
Zurück zum Zitat Birtley JR, Knox SR, Jaulent AM, Brick P, Leatherbarrow RJ, Curry S (2005) Crystal structure of foot-and-mouth disease virus 3C protease. New insights into catalytic mechanism and cleavage specificity. J Biol Chem 280:11520–11527CrossRefPubMed Birtley JR, Knox SR, Jaulent AM, Brick P, Leatherbarrow RJ, Curry S (2005) Crystal structure of foot-and-mouth disease virus 3C protease. New insights into catalytic mechanism and cleavage specificity. J Biol Chem 280:11520–11527CrossRefPubMed
2.
Zurück zum Zitat Mason PW, Chinsangaram J, Moraes MP, Mayr GA, Grubman MJ (2003) Engineering better vaccines for foot-and-mouth disease. Dev Biol 114:79–88 Mason PW, Chinsangaram J, Moraes MP, Mayr GA, Grubman MJ (2003) Engineering better vaccines for foot-and-mouth disease. Dev Biol 114:79–88
3.
Zurück zum Zitat Van Oirschot JT (1999) Diva vaccines that reduce virus transmission. J Biotechnol 73:195–205CrossRefPubMed Van Oirschot JT (1999) Diva vaccines that reduce virus transmission. J Biotechnol 73:195–205CrossRefPubMed
4.
Zurück zum Zitat Mingxiao M, Ningyi J, Juan LH, Min Z, Guoshun S, Guangze Z, Huijun L, Xiaowei H, Minglan J, Xu L, Haili M, Yue J, Gefen Y, Kuoshi J (2007) Immunogenicity of plasmids encoding P12A and 3C of FMDV and swine IL-18. Antiviral Res 76:59–67CrossRefPubMed Mingxiao M, Ningyi J, Juan LH, Min Z, Guoshun S, Guangze Z, Huijun L, Xiaowei H, Minglan J, Xu L, Haili M, Yue J, Gefen Y, Kuoshi J (2007) Immunogenicity of plasmids encoding P12A and 3C of FMDV and swine IL-18. Antiviral Res 76:59–67CrossRefPubMed
5.
Zurück zum Zitat Doel TR, Chong WKT (1982) Comparative immunogenicity of 146S, 75S, and 12S particles of foot-and-mouth disease virus. Arch Virol 73:185–191CrossRefPubMed Doel TR, Chong WKT (1982) Comparative immunogenicity of 146S, 75S, and 12S particles of foot-and-mouth disease virus. Arch Virol 73:185–191CrossRefPubMed
6.
Zurück zum Zitat Rweyemamu MM, Terry G, Pay TWF (1979) Stability and immunogenicity of empty particles of foot-and-mouth disease virus. Arch Virol 59:69–79CrossRefPubMed Rweyemamu MM, Terry G, Pay TWF (1979) Stability and immunogenicity of empty particles of foot-and-mouth disease virus. Arch Virol 59:69–79CrossRefPubMed
7.
Zurück zum Zitat Benvenisti L, Rogel A, Kuznetzova L, Bujanover S, Becker Y, Stram Y (2001) Gene gun-mediated DNA vaccination against foot-and-mouth disease virus. Vaccine 19:3885–3895CrossRefPubMed Benvenisti L, Rogel A, Kuznetzova L, Bujanover S, Becker Y, Stram Y (2001) Gene gun-mediated DNA vaccination against foot-and-mouth disease virus. Vaccine 19:3885–3895CrossRefPubMed
8.
Zurück zum Zitat Chinsangaram J, Beard C, Mason PW, Zellner MK, Ward G, Grubman MJ (1998) Antibody response in mice inoculated with DNA expressing foot-and-mouth disease virus capsid proteins. J Virol 72:4454–4457PubMed Chinsangaram J, Beard C, Mason PW, Zellner MK, Ward G, Grubman MJ (1998) Antibody response in mice inoculated with DNA expressing foot-and-mouth disease virus capsid proteins. J Virol 72:4454–4457PubMed
9.
Zurück zum Zitat Li Y, Aggarwal N, Takamatsu HH, Sterling CM, Voyce C, Barnett PV (2006) Enhancing immune responses against a plasmid DNA vaccine encoding a FMDV empty capsid from serotype O. Vaccine 24:4602–4606CrossRefPubMed Li Y, Aggarwal N, Takamatsu HH, Sterling CM, Voyce C, Barnett PV (2006) Enhancing immune responses against a plasmid DNA vaccine encoding a FMDV empty capsid from serotype O. Vaccine 24:4602–4606CrossRefPubMed
10.
Zurück zum Zitat Mayr GA, Chinsangaram J, Grubman MJ (1999) Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate. Virology 263:496–506CrossRefPubMed Mayr GA, Chinsangaram J, Grubman MJ (1999) Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate. Virology 263:496–506CrossRefPubMed
11.
Zurück zum Zitat Zheng M, Jin N, Zhang H, Jin M, Lu H, Ma M, Li C, Yin G, Wang R, Liu Q (2006) Construction and immunogenicity of a recombinant fowlpox virus containing the capsid and 3C protease coding regions of foot-and-mouth disease virus. J Virol Methods 136:230–237CrossRefPubMed Zheng M, Jin N, Zhang H, Jin M, Lu H, Ma M, Li C, Yin G, Wang R, Liu Q (2006) Construction and immunogenicity of a recombinant fowlpox virus containing the capsid and 3C protease coding regions of foot-and-mouth disease virus. J Virol Methods 136:230–237CrossRefPubMed
12.
Zurück zum Zitat Frimann TH, Barfoed AM, Aasted B, Kamstrup S (2007) Vaccination of mice with plasmids expressing processed capsid protein of foot-and-mouth disease virus-importance of dominant and subdominant epitopes for antigenicity and protection. Vaccine 25:6191–6200CrossRefPubMed Frimann TH, Barfoed AM, Aasted B, Kamstrup S (2007) Vaccination of mice with plasmids expressing processed capsid protein of foot-and-mouth disease virus-importance of dominant and subdominant epitopes for antigenicity and protection. Vaccine 25:6191–6200CrossRefPubMed
13.
Zurück zum Zitat Xiao C, Jin H, Hu Y, Kang Y, Wang J, Du X, Yang Y, She R, Wang B (2007) Enhanced protective efficacy and reduced viral load of foot-and-mouth disease DNA vaccine with co-stimulatory molecules as the molecular adjuvants. Antiviral Res 76:11–20CrossRefPubMed Xiao C, Jin H, Hu Y, Kang Y, Wang J, Du X, Yang Y, She R, Wang B (2007) Enhanced protective efficacy and reduced viral load of foot-and-mouth disease DNA vaccine with co-stimulatory molecules as the molecular adjuvants. Antiviral Res 76:11–20CrossRefPubMed
14.
Zurück zum Zitat Moraes M, Mayr GA, Mason PW, Grubman MJ (2002) Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Vaccine 20:1631–1639CrossRefPubMed Moraes M, Mayr GA, Mason PW, Grubman MJ (2002) Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Vaccine 20:1631–1639CrossRefPubMed
15.
Zurück zum Zitat Pacheco JM, Brum MC, Moraes MP, Golde WT, Grubman MJ (2005) Rapid protection of cattle from direct challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus-vectored FMDV subunit vaccine. Virology 337:205–209CrossRefPubMed Pacheco JM, Brum MC, Moraes MP, Golde WT, Grubman MJ (2005) Rapid protection of cattle from direct challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus-vectored FMDV subunit vaccine. Virology 337:205–209CrossRefPubMed
16.
Zurück zum Zitat McLean CS, Erturk M, Jennings R, Challanain DN, Minson AC, Duncan I, Boursnell ME, Inglis SC (1994) Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J Infect Dis 170:1100–1109PubMed McLean CS, Erturk M, Jennings R, Challanain DN, Minson AC, Duncan I, Boursnell ME, Inglis SC (1994) Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J Infect Dis 170:1100–1109PubMed
17.
Zurück zum Zitat De Avila Botton S, Brum MC, Bautista E, Koster M, Weiblen R, Golde WT, Grubman MJ (2006) Immunopotentiation of a foot-and-mouth disease virus subunit vaccine by interferon alpha. Vaccine 24:3446–3456CrossRefPubMed De Avila Botton S, Brum MC, Bautista E, Koster M, Weiblen R, Golde WT, Grubman MJ (2006) Immunopotentiation of a foot-and-mouth disease virus subunit vaccine by interferon alpha. Vaccine 24:3446–3456CrossRefPubMed
18.
Zurück zum Zitat Moraes MP, Chinsangaram J, Brum MC, Grubman MJ (2003) Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine. Vaccine 22:268–279CrossRefPubMed Moraes MP, Chinsangaram J, Brum MC, Grubman MJ (2003) Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine. Vaccine 22:268–279CrossRefPubMed
19.
Zurück zum Zitat Höhle C, Karger A, König P, Giesow K, Keil GM (2005) High-level expression of biologically active bovine alpha interferon by Bovine herpesvirus 1 interferes only marginally with recombinant virus replication in vitro. J Gen Virol 86:2685–2695CrossRefPubMed Höhle C, Karger A, König P, Giesow K, Keil GM (2005) High-level expression of biologically active bovine alpha interferon by Bovine herpesvirus 1 interferes only marginally with recombinant virus replication in vitro. J Gen Virol 86:2685–2695CrossRefPubMed
20.
Zurück zum Zitat Kühnle G, Collins RA, Scott JE, Keil GM (1996) Bovine interleukins 2 and 4 expressed in recombinant bovine herpesvirus 1 are biologically active secreted glycoproteins. J Gen Virol 77:2231–2240CrossRefPubMed Kühnle G, Collins RA, Scott JE, Keil GM (1996) Bovine interleukins 2 and 4 expressed in recombinant bovine herpesvirus 1 are biologically active secreted glycoproteins. J Gen Virol 77:2231–2240CrossRefPubMed
21.
Zurück zum Zitat König P, Beer M, Makoschey B, Teifke JP, Polster U, Giesow K, Keil GM (2003) Recombinant virus-expressed bovine cytokines do not improve efficacy of a bovine herpesvirus 1 marker vaccine strain. Vaccine 22:202–212CrossRefPubMed König P, Beer M, Makoschey B, Teifke JP, Polster U, Giesow K, Keil GM (2003) Recombinant virus-expressed bovine cytokines do not improve efficacy of a bovine herpesvirus 1 marker vaccine strain. Vaccine 22:202–212CrossRefPubMed
22.
Zurück zum Zitat Raggo C, Fitzpatrick DR, Babiuk LA, Liang X (1996) Expression of bovine interleukin-1 beta in a bovine herpesvirus-1 vector: in vitro analysis. Virology 221:78–86CrossRefPubMed Raggo C, Fitzpatrick DR, Babiuk LA, Liang X (1996) Expression of bovine interleukin-1 beta in a bovine herpesvirus-1 vector: in vitro analysis. Virology 221:78–86CrossRefPubMed
23.
Zurück zum Zitat Raggo C, Habermehl M, Babiuk LA, Griebel P (2000) The in vivo effects of recombinant bovine herpesvirus-1 expressing bovine interferon-gamma. J Gen Virol 81:2665–2673PubMed Raggo C, Habermehl M, Babiuk LA, Griebel P (2000) The in vivo effects of recombinant bovine herpesvirus-1 expressing bovine interferon-gamma. J Gen Virol 81:2665–2673PubMed
24.
Zurück zum Zitat Schmitt J, Becher P, Thiel HJ, Keil GM (1999) Expression of bovine viral diarrhoea virus glycoprotein E2 by bovine herpesvirus-1 from a synthetic ORF and incorporation of E2 into recombinant virions. J Gen Virol 80:2839–2848PubMed Schmitt J, Becher P, Thiel HJ, Keil GM (1999) Expression of bovine viral diarrhoea virus glycoprotein E2 by bovine herpesvirus-1 from a synthetic ORF and incorporation of E2 into recombinant virions. J Gen Virol 80:2839–2848PubMed
25.
Zurück zum Zitat Taylor G, Rijsewijk FA, Thomas LH, Wyld SG, Gaddum RM, Cook RS, Morrison WI, Hensen E, van Oirschot JT, Keil GM (1998) Resistance to bovine respiratory syncytial virus (BRSV) induced in calves by a recombinant bovine herpesvirus-1 expressing the attachment glycoprotein of BRSV. J Gen Virol 79:1759–1767PubMed Taylor G, Rijsewijk FA, Thomas LH, Wyld SG, Gaddum RM, Cook RS, Morrison WI, Hensen E, van Oirschot JT, Keil GM (1998) Resistance to bovine respiratory syncytial virus (BRSV) induced in calves by a recombinant bovine herpesvirus-1 expressing the attachment glycoprotein of BRSV. J Gen Virol 79:1759–1767PubMed
26.
Zurück zum Zitat MacLachlan NJ, Rosenquist BD (1982) Duration of protection of calves against rhinovirus challenge exposure by infectious bovine rhinotracheitis virus-induced interferon in nasal secretions. Am J Vet Res 43:289–293PubMed MacLachlan NJ, Rosenquist BD (1982) Duration of protection of calves against rhinovirus challenge exposure by infectious bovine rhinotracheitis virus-induced interferon in nasal secretions. Am J Vet Res 43:289–293PubMed
27.
Zurück zum Zitat Straub C, Ahl R (1976) Local interferon production in cattle after intranasal infection with avirulent IBR/IPV virus and its effect on a subsequent infection with foot-and-mouth disease virus. Zentralbl Veterinärmed B 23:470–482PubMed Straub C, Ahl R (1976) Local interferon production in cattle after intranasal infection with avirulent IBR/IPV virus and its effect on a subsequent infection with foot-and-mouth disease virus. Zentralbl Veterinärmed B 23:470–482PubMed
28.
Zurück zum Zitat Todd JD, Volenec FJ, Paton IM (1972) Interferon in nasal secretions and sera of calves after intranasal administration of avirulent infectious bovine rhinotracheitis virus: association of interferon in nasal secretions with early resistance to challenge with virulent virus. Infect Immun 5:699–706PubMed Todd JD, Volenec FJ, Paton IM (1972) Interferon in nasal secretions and sera of calves after intranasal administration of avirulent infectious bovine rhinotracheitis virus: association of interferon in nasal secretions with early resistance to challenge with virulent virus. Infect Immun 5:699–706PubMed
29.
Zurück zum Zitat Mayr GA, O’Donnell V, Chinsangaram J, Mason PW, Grubman MJ (2001) Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs. Vaccine 19:2152–2162CrossRefPubMed Mayr GA, O’Donnell V, Chinsangaram J, Mason PW, Grubman MJ (2001) Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs. Vaccine 19:2152–2162CrossRefPubMed
30.
Zurück zum Zitat Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual, 2nd edn. Cold Spring Harbor Laboratory, Cold Spring Harbor Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual, 2nd edn. Cold Spring Harbor Laboratory, Cold Spring Harbor
31.
Zurück zum Zitat Carrillo C, Tulman ER, Delhon G, Lu Z, Carreno A, Vagnozzi A, Kutish GF, Rock DL (2005) Comparative genomics of foot-and-mouth disease virus. J Virol 79:6487–6504CrossRefPubMed Carrillo C, Tulman ER, Delhon G, Lu Z, Carreno A, Vagnozzi A, Kutish GF, Rock DL (2005) Comparative genomics of foot-and-mouth disease virus. J Virol 79:6487–6504CrossRefPubMed
32.
Zurück zum Zitat Rodríguez A, Dopazo J, Sáiz JC, Sobrino F (1994) Immunogenicity of non-structural proteins of foot-and-mouth disease virus: differences between infected and vaccinated swine. Arch Virol 136:123–131CrossRefPubMed Rodríguez A, Dopazo J, Sáiz JC, Sobrino F (1994) Immunogenicity of non-structural proteins of foot-and-mouth disease virus: differences between infected and vaccinated swine. Arch Virol 136:123–131CrossRefPubMed
33.
Zurück zum Zitat Fehler F, Herrmann JM, Saalmüller A, Mettenleiter TC, Keil GM (1992) Glycoprotein IV of bovine herpesvirus 1-expressing cell line complements and rescues a conditionally lethal viral mutant. J Virol 66:831–839PubMed Fehler F, Herrmann JM, Saalmüller A, Mettenleiter TC, Keil GM (1992) Glycoprotein IV of bovine herpesvirus 1-expressing cell line complements and rescues a conditionally lethal viral mutant. J Virol 66:831–839PubMed
34.
Zurück zum Zitat Keil GM, Höhle C, Giesow K, König P (2005) Engineering glycoprotein B of bovine herpesvirus 1 to function as transporter for secreted proteins: a new protein expression approach. J Virol 79:791–799CrossRefPubMed Keil GM, Höhle C, Giesow K, König P (2005) Engineering glycoprotein B of bovine herpesvirus 1 to function as transporter for secreted proteins: a new protein expression approach. J Virol 79:791–799CrossRefPubMed
35.
Zurück zum Zitat Rauh I, Mettenleiter TC (1991) Pseudorabies virus glycoproteins gII and gp50 are essential for virus penetration. J Virol 65:5348–5356PubMed Rauh I, Mettenleiter TC (1991) Pseudorabies virus glycoproteins gII and gp50 are essential for virus penetration. J Virol 65:5348–5356PubMed
36.
Zurück zum Zitat Rowlands DJ, Sangar DV, Brown F (1975) A comparative chemical and serological study of the full and empty particles of foot-and mouth disease virus. J Gen Virol 26:227–238CrossRefPubMed Rowlands DJ, Sangar DV, Brown F (1975) A comparative chemical and serological study of the full and empty particles of foot-and mouth disease virus. J Gen Virol 26:227–238CrossRefPubMed
37.
Zurück zum Zitat Grubman MJ, Zellner M, Bablanian G, Mason PW, Piccone ME (1995) Identification of the active-site residues of the 3C proteinase of foot-and-mouth disease virus. Virology 213:581–589CrossRefPubMed Grubman MJ, Zellner M, Bablanian G, Mason PW, Piccone ME (1995) Identification of the active-site residues of the 3C proteinase of foot-and-mouth disease virus. Virology 213:581–589CrossRefPubMed
38.
Zurück zum Zitat Sibanda BL, Blundell TL, Thornton JM (1989) Conformation of beta-hairpins in protein structures. A systematic classification with applications to modelling by homology, electron density fitting and protein engineering. J Mol Biol 206:759–777CrossRefPubMed Sibanda BL, Blundell TL, Thornton JM (1989) Conformation of beta-hairpins in protein structures. A systematic classification with applications to modelling by homology, electron density fitting and protein engineering. J Mol Biol 206:759–777CrossRefPubMed
39.
Zurück zum Zitat Sweeney TR, Roqué-Rosell N, Birtley JR, Leatherbarrow RJ, Curry S (2007) Structural and mutagenic analysis of foot-and-mouth disease virus 3C protease reveals the role of the beta-ribbon in proteolysis. J Virol 81:115–124CrossRefPubMed Sweeney TR, Roqué-Rosell N, Birtley JR, Leatherbarrow RJ, Curry S (2007) Structural and mutagenic analysis of foot-and-mouth disease virus 3C protease reveals the role of the beta-ribbon in proteolysis. J Virol 81:115–124CrossRefPubMed
40.
Zurück zum Zitat Falk MM, Grigera PR, Bergmann IE, Zibert A, Multhaup G, Beck E (1990) Foot-and-mouth disease virus protease 3C induces specific proteolytic cleavage of host cell histone H3. J Virol 64:748–756PubMed Falk MM, Grigera PR, Bergmann IE, Zibert A, Multhaup G, Beck E (1990) Foot-and-mouth disease virus protease 3C induces specific proteolytic cleavage of host cell histone H3. J Virol 64:748–756PubMed
41.
Zurück zum Zitat Strong R, Belsham GJ (2004) Sequential modification of translation initiation factor eIF4GI by two different foot-and-mouth disease virus proteases within infected baby hamster kidney cells: identification of the 3Cpro cleavage site. J Gen Virol 85:2953–2962CrossRefPubMed Strong R, Belsham GJ (2004) Sequential modification of translation initiation factor eIF4GI by two different foot-and-mouth disease virus proteases within infected baby hamster kidney cells: identification of the 3Cpro cleavage site. J Gen Virol 85:2953–2962CrossRefPubMed
42.
Zurück zum Zitat Engels M, Giuliani C, Wild P, Beck TM, Loepfe E, Wyler R (1986) The genome of bovine herpesvirus 1 (BHV-1) strains exhibiting a neuropathogenic potential compared to known BHV-1 strains by restriction site mapping and cross-hybridization. Virus Res 6:57–73CrossRefPubMed Engels M, Giuliani C, Wild P, Beck TM, Loepfe E, Wyler R (1986) The genome of bovine herpesvirus 1 (BHV-1) strains exhibiting a neuropathogenic potential compared to known BHV-1 strains by restriction site mapping and cross-hybridization. Virus Res 6:57–73CrossRefPubMed
43.
Zurück zum Zitat Mayfield JE, Good PJ, VanOort HJ, Campbell AR, Reed DE (1983) Cloning and cleavage site mapping of DNA from bovine herpesvirus 1 (Cooper strain). J Virol 47:259–264PubMed Mayfield JE, Good PJ, VanOort HJ, Campbell AR, Reed DE (1983) Cloning and cleavage site mapping of DNA from bovine herpesvirus 1 (Cooper strain). J Virol 47:259–264PubMed
44.
Zurück zum Zitat Leung-Tack P, Audonnet JC, Riviere M (1994) The complete DNA sequence and the genetic organization of the short unique region (US) of the bovine herpesvirus type 1 (ST strain). Virology 199:409–421CrossRefPubMed Leung-Tack P, Audonnet JC, Riviere M (1994) The complete DNA sequence and the genetic organization of the short unique region (US) of the bovine herpesvirus type 1 (ST strain). Virology 199:409–421CrossRefPubMed
45.
Zurück zum Zitat Dorsch-Häsler K, Keil GM, Weber F, Jasin M, Schaffner W, Koszinowski UH (1985) A long and complex enhancer activates transcription of the gene coding for the highly abundant immediate early mRNA in murine cytomegalovirus. Proc Natl Acad Sci USA 82:8325–8329CrossRefPubMed Dorsch-Häsler K, Keil GM, Weber F, Jasin M, Schaffner W, Koszinowski UH (1985) A long and complex enhancer activates transcription of the gene coding for the highly abundant immediate early mRNA in murine cytomegalovirus. Proc Natl Acad Sci USA 82:8325–8329CrossRefPubMed
Metadaten
Titel
Effect of foot-and-mouth disease virus capsid precursor protein and 3C protease expression on bovine herpesvirus 1 replication
verfasst von
Constanze Klopfleisch
Luu Quang Minh
Katrin Giesow
Stephen Curry
Günther M. Keil
Publikationsdatum
01.05.2010
Verlag
Springer Vienna
Erschienen in
Archives of Virology / Ausgabe 5/2010
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-010-0648-6

Weitere Artikel der Ausgabe 5/2010

Archives of Virology 5/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.